Imatinib Base

Imatinib Base Specification

Molecular Formula
C29H31N7O

Molecular Weight
493.62 GSM (gm/2)

Medicine Name
Imatinib Base

Chemical Name
Imatinib Base

CAS No
152459-95-5

Type
Pharmaceutical Intermediates

Grade
Industrial Grade

Usage
It is used in oncology for caner treatment like breast and gastointestinal cancer.

Purity(%)
99%

Appearance
Off white powder

Physical Form
Powder

Imatinib Base Trade Information

Minimum Order Quantity
1 Kilograms

Delivery Time
1 Week

About Imatinib Base

Imatinib Base (CAS No. 152459-95-5), also known as Imatinib, CGP57148B, or by its marketed form as the active ingredient in Gleevec (also sold as Glivec), is a selective tyrosine kinase inhibitor widely used in oncology. It specifically targets the BCR-ABL fusion protein produced by the Philadelphia chromosome abnormality, as well as other tyrosine kinases such as c-KIT and PDGFR. Imatinib Base is the free base form of imatinib, typically used in pharmaceutical manufacturing before conversion into its mesylate salt form. It is primarily indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and is also used in gastrointestinal stromal tumors (GISTs) and certain other rare malignancies driven by kinase mutations. Its development marked a breakthrough in targeted cancer therapy by offering a mechanism-based treatment with improved specificity compared to traditional chemotherapy.